Akèy › Kansè Poumon ki pa ti selil › New York › Buffalo
Etid klinik pou Kansè Poumon ki pa ti selil nan Buffalo, NY
19 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Buffalo (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Ap rekriteFaz 3
- Roswell Park Cancer Institute, Buffalo
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Roswell Park Cancer Institute, Buffalo
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- Roswell Park Cancer Institute ( Site 0184), Buffalo
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Roswell Park Cancer Institute IDS, Buffalo
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Roswell Park Cancer Institute, Buffalo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Buffalo
Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Roswell Park Comprehensive Cancer Center, Buffalo
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Buffalo
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Buffalo
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Roswell Park Cancer Institute, Buffalo
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Roswell Park Comprehensive Cancer Center, Buffalo
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Roswell Park Comprehensive Cancer Center, Buffalo
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Roswell Park Cancer Institute, Buffalo
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Roswell Park Comprehensive Care Center, Buffalo
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Ap rekriteFaz 1
- Roswell Park Cancer Institute, Buffalo
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Ap rekriteFaz 1
- Roswell Cancer Institute, Buffalo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Buffalo
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
Ap rekrite
- Roswell Park Cancer Institute, Buffalo
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Roswell Park Cancer Institute, Buffalo
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Buffalo
- Kansè (tout kalite)19 etid
- Leksemi mieloïd egi19 etid
- Kansè poumon16 etid
- Kansè nan tete16 etid
- Kansè ovè13 etid
- Kansè Metastatik11 etid
- Kansè pwostat11 etid
- Melanom10 etid
- Myelom Miltip10 etid
- Obèsite9 etid
- Limfòm Burkitt8 etid
- Sendwòm myelodisplastik8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.